Aziyo Biologics and Boston Scientific Corporation Enter U.S. Sales Agent Agreement for CanGaroo® Envelope

Aziyo Biologics and Boston Scientific Corporation Enter U.S. Sales Agent Agreement for CanGaroo® Envelope
<span>Boston Scientific Sales Agents to Begin Selling Aziyo&rsquo;s CanGaroo May 1st SILVER SPRING, MD. &ndash; May 1, 2019 &ndash; Aziyo Biologics, Inc., a fully integrated, commercially oriented regenerative medicine company, announced that it has entered into a U.S. sales agent agreement for its CanGaroo&reg; Envelope with Boston Scientific Corporation, a global medical...</span>

Boston Scientific Sales Agents to Begin Selling Aziyo’s CanGaroo May 1st

SILVER SPRING, MD. – May 1, 2019 – Aziyo Biologics, Inc., a fully integrated, commercially oriented regenerative medicine company, announced that it has entered into a U.S. sales agent agreement for its CanGaroo® Envelope with Boston Scientific Corporation, a global medical technology leader. The agreement provides a commercial framework under which Boston Scientific’s 850 sales agents will work in conjunction with Aziyo’s existing commercial organization to drive adoption of the CanGaroo Envelope. CanGaroo, a 510(k) FDA-cleared and CE-Marked medical device, is manufactured from a natural extracellular matrix (ECM) scaffold that securely anchors cardiovascular implantable electronic devices (CIEDs) to create a stable environment conducive to healing following implantation.

“This partnership with Boston Scientific will allow Aziyo to leverage an extensive and established network of clinical and sales professionals to significantly expand the availability of the CanGaroo to more hospitals, physicians and patients receiving CIEDs,” said Ron Lloyd, Chief Executive Officer of Aziyo Biologics. “Our ECM envelopes allow physicians to better manage and potentially avoid complications associated with this patient population, and we believe the unparalleled level of market access that this agreement provides for will meaningfully impact the adoption curve of CanGaroo in the U.S.”

Each year in the United States more than 600,000 CIED implant procedures are performed1. These devices are routinely removed and/or replaced for reasons such as device upgrade, battery replacement or general complications associated with the device implantation. The use of CanGaroo at CIED implant has become a widely recognized and accepted practice which may reduce some of the complexity and complications associated with these procedures.

In vivo studies have demonstrated that use of CanGaroo when implanting CIEDs reduces the risk of device migration and erosion and may facilitate device removal when future exchange or revision is required1. Because it is constructed of biologic ECM, once CanGaroo is implanted, evidence shows that it remodels over time into a vascularized pocket surrounding the CIED. CanGaroo is available in five sizes in the United States for use with the full spectrum of transvenous and subcutaneous CIEDs.

The CanGaroo Envelope is a 510(k) FDA-cleared and CE-Marked medical device constructed from a multi-laminate sheet of decellularized, non-crosslinked, lyophilized ECM derived from porcine small intestinal submucosa (SIS). Upon implantation, CanGaroo secures CIEDs in place, and has been shown in in vivo studies to remodel into a vascularized pocket that may facilitate implant removal or revision when required.

About Aziyo Biologics, Inc.

Aziyo Biologics is a fully integrated, commercially oriented regenerative medicine company. Since its founding in 2015 the Company has expanded through acquisitions and strategic partnerships, creating a high-growth commercial entity. Its proprietary products are used in orthopedic, cardiovascular and other medical specialties. For more information, visit www.Aziyo.com.

For additional information, please contact:

Courtney Guyer
Aziyo Biologics, Inc.
Phone: (510) 730-7896
PR@aziyo.com

1. Data on file with Aziyo

Source: www.aziyo.com